Sensei Biotherapeutics, a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, completed the acquisition of Alvaxa Biosciences, a camelid antibody therapeutics company. Financial terms were not disclosed. “We are delighted to announce the acquisition of Alvaxa Biosciences. Nanobodies are the next stage of our strategy to build out our proprietary ImmunoPhage™ platform, a next-generation universal vaccine platform capable of driving precise antigen-specific immunity while also amplifying or attenuating key immune signals, all within a vaccine,” John Celebi, Sensei Biotherapeutics President and CEO.